$810 Million is the total value of Samsara BioCapital, LLC's 50 reported holdings in Q2 2021. The portfolio turnover from Q1 2021 to Q2 2021 was 18.2% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| GRPH | New | Graphite Bio Inc | $228,374,000 | – | 7,431,623 | +100.0% | 28.19% | – |
| NKTX | Nkarta, Inc. | $64,480,000 | -3.7% | 2,034,703 | 0.0% | 7.96% | -35.5% | |
| KDNY | Chinook Therapeutics Inc | $44,738,000 | -9.1% | 3,168,388 | 0.0% | 5.52% | -39.2% | |
| NVAX | Novavax, Inc.call | $42,165,000 | +17.1% | 198,600 | 0.0% | 5.20% | -21.6% | |
| TIL | Buy | Instil Bio Inc | $41,449,000 | +6.3% | 2,145,395 | +38.1% | 5.12% | -28.8% |
| FMTX | Forma Therapeutics Holdings, Inc. | $38,966,000 | -11.2% | 1,565,529 | 0.0% | 4.81% | -40.5% | |
| CNTA | New | Centessa Pharmaceuticals PLCspons ads | $34,149,000 | – | 1,537,533 | +100.0% | 4.22% | – |
| STRO | Sutro BioPharma Inc | $31,149,000 | -18.3% | 1,675,579 | 0.0% | 3.84% | -45.3% | |
| RXRX | New | Recursion Pharmaceuticals Inc | $28,309,000 | – | 775,583 | +100.0% | 3.50% | – |
| RAIN | New | Rain Therapeutics Inc | $25,444,000 | – | 1,637,308 | +100.0% | 3.14% | – |
| JANX | New | Janux Therapeutics Inc. | $15,168,000 | – | 607,949 | +100.0% | 1.87% | – |
| SWTX | Springworks Therapeutics Inc | $13,998,000 | +12.0% | 169,852 | 0.0% | 1.73% | -25.0% | |
| ACRS | Sell | Aclaris Therapeutics, Inc. | $13,946,000 | -45.9% | 794,171 | -22.3% | 1.72% | -63.8% |
| ISEE | Sell | Iveric Bio, Inc. | $13,411,000 | -8.5% | 2,125,371 | -10.4% | 1.66% | -38.8% |
| ICPT | Intercept Pharmaceuticals Inc | $12,795,000 | -13.5% | 640,688 | 0.0% | 1.58% | -42.1% | |
| ELEV | New | Elevation Oncology Inc | $12,650,000 | – | 932,239 | +100.0% | 1.56% | – |
| ALLK | Allakos Inc | $12,486,000 | -25.6% | 146,259 | 0.0% | 1.54% | -50.2% | |
| BOLT | Bolt Biotherapeutics, Inc | $11,401,000 | -53.0% | 737,459 | 0.0% | 1.41% | -68.6% | |
| SYRS | Syros Pharmaceuticals Inc | $10,599,000 | -28.2% | 2,189,199 | 0.0% | 1.31% | -52.0% | |
| VIRX | Sell | Viracta Therapeutics Inc | $8,063,000 | +4.8% | 711,039 | -14.5% | 1.00% | -29.9% |
| VRNA | Verona Pharma PLC.spons ads | $7,267,000 | -21.8% | 1,111,112 | 0.0% | 0.90% | -47.6% | |
| DBTX | Decibel Therapeutics Inc | $7,107,000 | -24.3% | 826,422 | 0.0% | 0.88% | -49.3% | |
| ALLK | Allakos Inccall | $7,086,000 | -25.6% | 83,000 | 0.0% | 0.88% | -50.2% | |
| NVAX | Novavax, Inc. | $6,403,000 | +17.1% | 30,160 | 0.0% | 0.79% | -21.6% | |
| AGLE | Aeglea BioTherapeutics, Inc. | $6,151,000 | -12.1% | 883,720 | 0.0% | 0.76% | -41.2% | |
| RYTM | Buy | Rhythm Pharmaceuticals Inc | $5,880,000 | +37.5% | 300,293 | +49.4% | 0.73% | -8.0% |
| BCTG | BCTG Acquisition Corp | $5,690,000 | +2.3% | 500,000 | 0.0% | 0.70% | -31.5% | |
| JYAC | Jiya Acquisition Corp | $5,040,000 | +1.0% | 507,041 | 0.0% | 0.62% | -32.4% | |
| DAWN | New | Day One Biopharmaceuticals | $4,611,000 | – | 202,500 | +100.0% | 0.57% | – |
| EQ | Sell | Equillium, Inc. | $4,348,000 | -20.4% | 738,176 | -3.4% | 0.54% | -46.7% |
| EYPT | Eyepoint Pharmaceuticals Inc | $4,046,000 | -11.5% | 450,000 | 0.0% | 0.50% | -40.8% | |
| AVDL | Avadel Pharmaceuticals PLCspons adr | $3,696,000 | -25.6% | 549,250 | 0.0% | 0.46% | -50.2% | |
| TERN | Sell | Terns Pharmaceuticals, Inc | $3,544,000 | -67.6% | 289,068 | -41.9% | 0.44% | -78.4% |
| ALBO | Albireo Pharma, Inc. | $3,518,000 | -0.2% | 100,000 | 0.0% | 0.43% | -33.2% | |
| BCEL | Atreca Inc | $3,381,000 | -44.4% | 396,835 | 0.0% | 0.42% | -62.8% | |
| KALA | Kala Pharmaceuticals Inc | $3,186,000 | -21.4% | 601,162 | 0.0% | 0.39% | -47.4% | |
| BLSA | BCLS Acquisition Corp | $3,159,000 | -0.4% | 300,000 | 0.0% | 0.39% | -33.3% | |
| CHFWU | Consonance HFW Acquisition Co | $3,120,000 | +6.6% | 300,000 | 0.0% | 0.38% | -28.7% | |
| IMCR | Sell | Immunocore Holdings Limitedspons ads | $2,499,000 | -26.6% | 64,000 | -20.0% | 0.31% | -51.0% |
| ALPN | Sell | Alpine Immune Sciences Inc | $2,477,000 | -41.5% | 275,169 | -31.1% | 0.31% | -60.8% |
| ODT | Odonate Therapeutics Inc | $2,444,000 | +2.0% | 700,421 | 0.0% | 0.30% | -31.7% | |
| VTGN | Sell | Vistagen Therapeutics Inc | $2,308,000 | -40.8% | 732,596 | -60.0% | 0.28% | -60.4% |
| LSAQ | Lifesci Acquisition II Corp | $2,000,000 | -1.4% | 200,000 | 0.0% | 0.25% | -34.0% | |
| KRON | Sell | Kronos Bio Inc | $1,871,000 | -61.5% | 78,131 | -53.0% | 0.23% | -74.2% |
| RCKT | Sell | Rocket Pharmaceuticals Inc | $1,796,000 | -36.5% | 40,550 | -36.4% | 0.22% | -57.5% |
| ALVR | Allovir, Inc | $1,625,000 | -15.7% | 82,336 | 0.0% | 0.20% | -43.4% | |
| BNTX | Sell | BioNTech SEspons ads | $1,289,000 | +9.3% | 5,758 | -46.7% | 0.16% | -26.7% |
| NGM | NGM Biopharmaceuticals, Inc. | $359,000 | -32.3% | 18,225 | 0.0% | 0.04% | -55.1% | |
| Catabasis Pharmaceuticals Inc | $317,000 | -27.0% | 150,000 | 0.0% | 0.04% | -51.2% | ||
| AMRN | Amarin Corp PLCspons adr new | $110,000 | -29.0% | 25,000 | 0.0% | 0.01% | -51.7% | |
| CVAC | Exit | CureVac N.V. | $0 | – | -95,318 | -100.0% | -1.61% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-08-17
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Intercept Pharmaceuticals Inc | 20 | Q3 2023 | 24.0% |
| ALLAKOS INC | 20 | Q3 2023 | 23.0% |
| SUTRO BIOPHARMA INC | 20 | Q3 2023 | 10.1% |
| SYROS PHARMACEUTICALS INC | 16 | Q3 2022 | 11.6% |
| ATRECA INC | 16 | Q1 2023 | 7.4% |
| IVERIC BIO INC | 15 | Q2 2023 | 5.5% |
| ACLARIS THERAPEUTICS INC | 15 | Q3 2023 | 4.8% |
| RHYTHM PHARMACEUTICALS INC | 15 | Q3 2023 | 2.4% |
| ODONATE THERAPEUTICS INC | 14 | Q1 2022 | 14.9% |
| SPRINGWORKS THERAPEUTICS INC | 14 | Q4 2022 | 12.1% |
View Samsara BioCapital, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR/A | 2023-08-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR/A | 2023-02-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
View Samsara BioCapital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.